Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer (NCT03678025)
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
🩺 Plain-English Summary (8th-Grade Level)
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Who can join: Review the eligibility criteria below.
Location: Banner MD Anderson Cancer Center — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (338 Sites)
Showing the first 25 of 338 sites.
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Cancer Center at Saint Joseph's — Phoenix, Arizona
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- Mayo Clinic in Arizona — Scottsdale, Arizona
- University of Arizona Cancer Center-Orange Grove Campus — Tucson, Arizona
- University of Arizona Cancer Center-North Campus — Tucson, Arizona
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- Community Cancer Institute — Clovis, California
- University Oncology Associates — Clovis, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- Kaiser Permanente Dublin — Dublin, California
- Kaiser Permanente-Fremont — Fremont, California
- Fresno Cancer Center — Fresno, California
- Kaiser Permanente-Fresno — Fresno, California
- UC San Diego Moores Cancer Center — La Jolla, California
- Tibor Rubin VA Medical Center — Long Beach, California
- Los Angeles County-USC Medical Center — Los Angeles, California
- USC / Norris Comprehensive Cancer Center — Los Angeles, California
- Fremont - Rideout Cancer Center — Marysville, California
- Kaiser Permanente-Modesto — Modesto, California
- Kaiser Permanente Oakland-Broadway — Oakland, California
- Kaiser Permanente-Oakland — Oakland, California
- Desert Regional Medical Center — Palm Springs, California
- Stanford Cancer Institute Palo Alto — Palo Alto, California
📞 Contact the Study Coordinator
Phone: (210) 614-8808
Email: dsparks@swog.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Castration Levels of Testosterone
- Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer — Houston, Texas
- Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel — Fairbanks, Alaska
Explore by condition: All Castration Levels of Testosterone clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.